Rita Nanda

42PUBLICATIONS
275CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsMolecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (42)

|Apr 22, 2026
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer.

|Apr 20, 2026
Single-Cell Profiling Reveals a Treg-Rich, NK Cell-Depleted Immune Microenvironment in Triple-Negative Breast Cancer with High-Glucocorticoid Receptor Expression.

|Mar 10, 2026
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.

Natasha B Hunter, Heather A Parsons, Leslie Cope

|Jan 28, 2026
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.

Nadine M Tung, Mark E Robson, Tianyu Li

|Sep 12, 2025
Clinical Outcomes and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapy in Breast Cancer With Uncommon In Situ Hybridization Patterns or Discordant Immunohistochemistry.

Qianchen Zhang, Jincong Q Freeman, Fangyuan Zhao

|Jun 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.

Denise M Wolf, Christina Yau, Michael Campbell

Pageof 7

Frequent Collaborators

10 joint publications

Claudine Isaacs

10 joint publications

Laura J Esserman

9 joint publications

Frederick M Howard

9 joint publications

Laura van 't Veer